An interim report of the Scleroderma Clinical Trials Consortium working groups
暂无分享,去创建一个
P. Merkel | M. Hudson | M. Baron | Sindhu R. Johnson | J. Gordon | R. Domsic | C. Denton | D. Khanna | P. Clements | L. Chung | B. Kahaleh | S. Narain | T. Frech | E. Bernstein | N. Ferdowsi | I. Foeldvari | Z. McMahan | M. Nikpour | J. Pauling | L. Ross | Antonia Maria Valenzuela Vergara | A. Vacca | S. Johnson | P. Merkel
[1] R. Domsic,et al. Multinational Qualitative Research Study Exploring the Patient Experience of Raynaud's Phenomenon in Systemic Sclerosis , 2018, Arthritis care & research.
[2] R. Domsic,et al. Patient Perceptions of the Raynaud's Condition Score Diary Provide Insight Into Its Performance in Clinical Trials of Raynaud's Phenomenon: Comment on the Article by Denton et al , 2018, Arthritis & rheumatology.
[3] John Allen,et al. A Multicenter Study of the Validity and Reliability of Responses to Hand Cold Challenge as Measured by Laser Speckle Contrast Imaging and Thermography , 2018, Arthritis & rheumatology.
[4] A. Herrick,et al. Efficacy and Safety of Selexipag in Adults With Raynaud's Phenomenon Secondary to Systemic Sclerosis , 2017, Arthritis & rheumatology.
[5] Sun Ku Lee,et al. Novel lung imaging biomarkers and skin gene expression subsetting in dasatinib treatment of systemic sclerosis-associated interstitial lung disease , 2017, PloS one.
[6] A. Martini,et al. Extrapolation or controlled trials in paediatrics: the current dilemma , 2017, Archives of Disease in Childhood.
[7] J. Schwitter,et al. Cardiovascular magnetic resonance in systemic sclerosis: "Pearls and pitfalls". , 2017, Seminars in arthritis and rheumatism.
[8] M. Emdin,et al. High sensitivity troponin might be a marker of subclinical scleroderma heart involvement: a preliminary study , 2017 .
[9] F. Springer,et al. SASHA versus ShMOLLI: a comparison of T1 mapping methods in health and dilated cardiomyopathy at 3 T , 2017, The International Journal of Cardiovascular Imaging.
[10] R. Hemmings,et al. Extrapolation in the development of paediatric medicines: examples from approvals for biological treatments for paediatric chronic immune-mediated inflammatory diseases , 2017, Archives of Disease in Childhood.
[11] M. Hudson,et al. Patient participation in patient-reported outcome instrument development in systemic sclerosis. , 2017, Clinical and experimental rheumatology.
[12] M. Hudson,et al. Early Mortality in a Multinational Systemic Sclerosis Inception Cohort , 2017, Arthritis & rheumatology.
[13] M. Hudson,et al. Towards developing criteria for scleroderma renal crisis: A scoping review. , 2017, Autoimmunity reviews.
[14] J. Gordon,et al. Reliability and Validity of the Tender and Swollen Joint Counts and the Modified Rodnan Skin Score in Early Diffuse Cutaneous Systemic Sclerosis: Analysis from the Prospective Registry of Early Systemic Sclerosis Cohort , 2017, The Journal of Rheumatology.
[15] M. Hudson,et al. Measures of disease status in systemic sclerosis: A systematic review. , 2017, Seminars in arthritis and rheumatism.
[16] Oliver Distler,et al. Standardization of the Modified Rodnan Skin Score for Use in Clinical Trials of Systemic Sclerosis , 2017, Journal of scleroderma and related disorders.
[17] M. Baron,et al. Calcinosis is associated with digital ulcers and osteoporosis in patients with systemic sclerosis: A Scleroderma Clinical Trials Consortium study. , 2016, Seminars in arthritis and rheumatism.
[18] M. Baron,et al. The European Scleroderma Trials and Research group (EUSTAR) task force for the development of revised activity criteria for systemic sclerosis: derivation and validation of a preliminarily revised EUSTAR activity index , 2016, Annals of the rheumatic diseases.
[19] K. Brown,et al. Design of a randomised, placebo-controlled clinical trial of nintedanib in patients with systemic sclerosis-associated interstitial lung disease (SENSCIS™). , 2016, Clinical and experimental rheumatology.
[20] G. Raghu,et al. An Open-label, Phase II Study of the Safety and Tolerability of Pirfenidone in Patients with Scleroderma-associated Interstitial Lung Disease: the LOTUSS Trial , 2016, The Journal of Rheumatology.
[21] R. Elashoff,et al. Mycophenolate Mofetil versus Oral Cyclophosphamide in Scleroderma-related Interstitial Lung Disease: Scleroderma Lung Study II (SLS-II), a double-blind, parallel group, randomised controlled trial , 2016, The Lancet. Respiratory medicine.
[22] A. Herrick,et al. Systemic sclerosis-related calcinosis , 2016 .
[23] M. Baron,et al. Late Nailfold Videocapillaroscopy Pattern Associated With Hand Calcinosis and Acro‐Osteolysis in Systemic Sclerosis , 2016, Arthritis care & research.
[24] M. Mayes,et al. The American College of Rheumatology Provisional Composite Response Index for Clinical Trials in Early Diffuse Cutaneous Systemic Sclerosis , 2016, Arthritis & rheumatology.
[25] A. Herrick,et al. Calcinosis preferentially affects the thumb compared to other fingers in patients with systemic sclerosis , 2016, Scandinavian journal of rheumatology.
[26] Jacqueline A Shipley,et al. Use of Laser Speckle Contrast Imaging to Assess Digital Microvascular Function in Primary Raynaud Phenomenon and Systemic Sclerosis: A Comparison Using the Raynaud Condition Score Diary , 2015, The Journal of Rheumatology.
[27] D. Borderie,et al. Cardiac Biomarkers in Systemic Sclerosis: Contribution of High‐Sensitivity Cardiac Troponin in Addition to N‐Terminal Pro‐Brain Natriuretic Peptide , 2015, Arthritis care & research.
[28] M. Baron,et al. SYSTEMIC SCLEROSIS RELATED CALCINOSIS: PATIENTS PROVIDE WHAT SPECIALISTS WANT TO LEARN. , 2015, The Journal of the Louisiana State Medical Society : official organ of the Louisiana State Medical Society.
[29] C. Hutchinson,et al. Validation of a Novel Radiographic Scoring System for Calcinosis Affecting the Hands of Patients With Systemic Sclerosis , 2015, Arthritis care & research.
[30] R. Hays,et al. Construct Validity of the Patient‐Reported Outcomes Measurement Information System Gastrointestinal Symptom Scales in Systemic Sclerosis , 2014, Arthritis care & research.
[31] M. Mayes,et al. Multicriteria decision analysis methods with 1000Minds for developing systemic sclerosis classification criteria. , 2014, Journal of clinical epidemiology.
[32] M. Hudson,et al. Exposure to ACE inhibitors prior to the onset of scleroderma renal crisis-results from the International Scleroderma Renal Crisis Survey. , 2014, Seminars in arthritis and rheumatism.
[33] W. Chey,et al. Measuring response in the gastrointestinal tract in systemic sclerosis , 2013, Current opinion in rheumatology.
[34] L. Czirják,et al. Joint and tendon involvement predict disease progression in systemic sclerosis: a EUSTAR prospective study , 2013, Annals of the rheumatic diseases.
[35] H. Paulus,et al. Evaluation of Test Characteristics for Outcome Measures Used in Raynaud's Phenomenon Clinical Trials , 2013, Arthritis care & research.
[36] F. Zulian,et al. A preliminary disease severity score for juvenile systemic sclerosis. , 2012, Arthritis and rheumatism.
[37] D. Furst,et al. Articular involvement in systemic sclerosis. , 2012, Rheumatology.
[38] D. Furst,et al. Arthritis in systemic sclerosis: systematic review of the literature and suggestions for the performance of future clinical trials in systemic sclerosis arthritis. , 2012, Seminars in arthritis and rheumatism.
[39] D. Wetter,et al. Calcinosis cutis in autoimmune connective tissue diseases , 2012, Dermatologic therapy.
[40] F. Houssiau,et al. Hand radiological damage in systemic sclerosis: comparison with a control group and clinical and functional correlations. , 2011, Seminars in arthritis and rheumatism.
[41] N. Tamimi,et al. Modified-release sildenafil reduces Raynaud's phenomenon attack frequency in limited cutaneous systemic sclerosis. , 2011, Arthritis and rheumatism.
[42] Y. Allanore,et al. Predictive factors of hand radiographic lesions in systemic sclerosis: a prospective study , 2010, Annals of the rheumatic diseases.
[43] Y. Allanore,et al. Primary myocardial involvement in systemic sclerosis: evidence for a microvascular origin. , 2010, Clinical and experimental rheumatology.
[44] M. Matucci-Cerinic,et al. Characteristics of Joint Involvement and Relationships with Systemic Inflammation in Systemic Sclerosis: Results from the EULAR Scleroderma Trial and Research Group (EUSTAR) Database , 2010, The Journal of Rheumatology.
[45] A. Silman,et al. Incidence of childhood linear scleroderma and systemic sclerosis in the UK and Ireland , 2010, Arthritis care & research.
[46] D. Furst,et al. Sensitivity to change of the modified Rodnan skin score in diffuse systemic sclerosis--assessment of individual body sites in two large randomized controlled trials. , 2009, Rheumatology.
[47] Y. Allanore,et al. N-terminal pro brain natriuretic peptide: the new cornerstone of cardiovascular assessment in systemic sclerosis. , 2009, Clinical and experimental rheumatology.
[48] P. Tugwell,et al. OMERACT: An international initiative to improve outcome measurement in rheumatology , 2007, Trials.
[49] M. Mayes,et al. Development of a provisional core set of response measures for clinical trials of systemic sclerosis , 2007, Annals of the rheumatic diseases.
[50] T. Medsger,et al. Changes in causes of death in systemic sclerosis, 1972–2002 , 2007, Annals of the rheumatic diseases.
[51] P. Emery,et al. A multicenter, prospective, randomized, double-blind, placebo-controlled trial of corticosteroids and intravenous cyclophosphamide followed by oral azathioprine for the treatment of pulmonary fibrosis in scleroderma. , 2006, Arthritis and rheumatism.
[52] Charlie Strange,et al. Cyclophosphamide versus placebo in scleroderma lung disease. , 2006, The New England journal of medicine.
[53] T. Medsger,et al. Improvement in skin thickening in systemic sclerosis associated with improved survival. , 2001, Arthritis and rheumatism.
[54] A. Silman,et al. European multicentre study to define disease activity criteria for systemic sclerosis.* II. Identification of disease activity variables and development of preliminary activity indexes , 2001, Annals of the rheumatic diseases.
[55] T. Medsger,et al. Severe organ involvement in systemic sclerosis with diffuse scleroderma. , 2000, Arthritis and rheumatism.
[56] Richard W. Martin,et al. Skin thickness score as a predictor and correlate of outcome in systemic sclerosis: high-dose versus low-dose penicillamine trial. , 2000, Arthritis and rheumatism.
[57] A. Silman,et al. A disease severity scale for systemic sclerosis: development and testing. , 1999, The Journal of rheumatology.
[58] Richard W. Martin,et al. Oral iloprost treatment in patients with Raynaud's phenomenon secondary to systemic sclerosis: a multicenter, placebo-controlled, double-blind study. , 1998, Arthritis and rheumatism.
[59] T. Medsger,et al. The palpable tendon friction rub: an important physical examination finding in patients with systemic sclerosis. , 1997, Arthritis and rheumatism.
[60] T. Medsger,et al. The palpable tendon friction rub , 1997 .
[61] Richard W. Martin,et al. Inter and intraobserver variability of total skin thickness score (modified Rodnan TSS) in systemic sclerosis. , 1995, The Journal of rheumatology.
[62] E. Keystone,et al. The articular manifestations of progressive systemic sclerosis (scleroderma). , 1982, Annals of the rheumatic diseases.
[63] G. Hutchins,et al. Myocardial Lesions of Progressive Systemic Sclerosis: A Cause of Cardiac Dysfunction , 1976, Circulation.
[64] J. Fries,et al. Pathologic observations in systemic sclerosis (scleroderma). A study of fifty-eight autopsy cases and fifty-eight matched controls. , 1969, The American journal of medicine.
[65] L. Saketkoo,et al. The patient experience of Raynaud’s phenomenon in systemic sclerosis , 2019, Rheumatology.
[66] Ankoor S. Shah,et al. Attitudes Toward Patient-Reported Outcome Instruments for the Assessment of Raynaud’s Phenomenon in Systemic Sclerosis , 2016 .
[67] M. Mayes,et al. Assessment of kidney involvement. , 2003, Clinical and experimental rheumatology.
[68] Kathryn Fitch,et al. The RAND/UCLA Appropriateness Method User's Manual , 2001 .
[69] C. Hutchinson,et al. Concise Report , 2022 .